Sleep disorders are increasing at an alarming rate with insomnia affecting nearly one third of the world population. The mechanisms of wakefulness and sleep are intricate. The main pathophysiology involves the interplay of inhibitory neurotransmitters especially GABA. Another neuroransmitter orexin which was earlier considered to be responsible for the satiety control was also found to be responsible for maintaining arousal. With the efforts of numerous researchers, two types of orexin receptors were discovered. This led to development of Dual Orexin Receptor Antagonist (DORA),Daridorexant which was recently approved by the FDA for sleep related disorders and to improve the overall sleep quality. This review elucidates the currently available information regarding Daridorexant.